Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod

Merck & Co., Inc. MRK continues to find success with its product pipeline, with another of its treatment options receiving FDA approval. 

Merck announced Wednesday that the FDA OK'd RECARBIO, a combination of imipenem, cilastatin and relebactam in a 1.25g injection formulation.

The drug is intended to treat patients 18 and older for complicated urinary tract infection, or cUTI — including pyelonephritis — caused by some susceptible gram-negative microorganisms and for which there is limited or no alternative treatment options.

The antibacterial medication is also indicated to treat complicated intra-abdominal infections.

"RECARBRIO offers an additional treatment option for patients with cIAI and cUTI who have limited and, in some cases, no alternative therapeutic options," Keith Kaye, a principal investigator of the clinical program that evaluated the antibiotic combo, said in a statement. 

Merck shares were trading higher by 0.42% at $81.93 at the time of publication Wednesday. 

Related Links:

Merck Strikes $773M Deal For Privately Held Tilos Therapeutics

Washington Worries Trigger Bearish Merck Options Trades

Posted In: BiotechNewsFDATrading IdeasGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...